Farletuzumab radioimmunotherapy - Morphotek/University of Gothenburg

Drug Profile

Farletuzumab radioimmunotherapy - Morphotek/University of Gothenburg

Latest Information Update: 07 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Morphotek; University of Gothenburg
  • Class Drug conjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Ovarian cancer

Most Recent Events

  • 17 Nov 2015 Morphotek and the University of Gothenburg agree to co-develop farletuzumab radioimmunotherapy for Ovarian cancer
  • 17 Nov 2015 Early research in Ovarian cancer (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top